Boiron's Sales Grow Double-Digits In 2022 Despite Difficult End To Year
French homeopathy specialist Boiron enjoyed a good 2022 after a few challenging years as a result of COVID-19 and France's decision to exclude homeopathic medicines from health insurance coverage.
You may also be interested in...
Boiron's decision to diversify its portfolio away from non-proprietary homeopathic medicines is paying off, with sales for the opening nine months of 2022 up by a quarter, driven by new product launches in categories such as cosmetics and dietary supplements.
France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.
Advancing personalized consumer innovation in healthy aging is the goal of a new partnership between Bayer and biological age test development firm Hurdle.